Valuation: Mertiva AB

Market Cap 772M 675M 623M 574M 1.08B 74.39B 1.11B 7.45B 2.93B 36.43B 2.9B 2.84B 125B P/E 2018
28.3x
P/E 2019 13.3x
Enterprise Value 689M 602M 556M 512M 966M 66.39B 987M 6.65B 2.61B 32.52B 2.59B 2.53B 112B EV / Sales 2018
-
EV / Sales 2019 -
Free-Float
68.13%
Yield 2018 *
-
Yield 2019 -
27/08/17 Sanofi Pasteur Inc. completed the acquisition of Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others. CI
10/08/17 Diamyd Medical and Cardiff University to Collaborate on Study Monitoring Immune Response in Lymph Node Cells After Administration of Diamyd CI
10/07/17 Sanofi Pasteur Inc. agreed to acquire Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others for $750 million CI
28/11/15 Mertiva AB's Equity Buyback announced on December 6, 2012, has expired. CI
18/12/14 Mertiva AB (OTCPK:DMYD.F) acquired an additional 0.54% stake in Protein Sciences Corporation for $0.62 million. CI
21/01/14 Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012. CI
11/10/13 Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012. CI
08/10/13 The members of the management of Diamyd, Inc. cancelled the acquisition of 90% stake in Diamyd Inc. from Diamyd Medical AB (OM:DIAM B). CI
25/09/13 Mertiva AB (OTCPK:DMYD.F) acquired an additional 7.27% stake in Protein Sciences Corporation from Pacific Rim Ventures Co., Ltd. and other shareholders for $8.4 million. CI
27/08/13 Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic All-Share Index CI
30/07/13 Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic Small Cap Index CI
04/07/13 Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012. CI
23/04/13 Diamyd Medical AB Announces Board Appointments CI
Date Insider Type Main position Quantity % Market Cap.
14/10/20 Buy

Chairman

24,314 0.1775%
08/10/20 Buy

Chairman

5,378 0.0393%
08/10/20 Buy

Chairman

6,321 0.0461%
Change 5-day change 1-year change 3-year change Capi.($)
- 0.00% - - 89.46M
-1.29%-3.11%-0.39%+4.92% 49.7B
+3.31%-0.77%+374.90%+596.92% 38.09B
-1.40%+4.67%+7.68%+57.98% 35.29B
-2.09%-0.75%+26.37%-6.81% 35.13B
+0.06%+1.56%+4.41%+27.42% 27.22B
+1.86%-1.96% - - 16.14B
-0.14%+0.19%+68.95%+117.99% 15.36B
+1.12%+1.91%+15.90%+19.65% 13.89B
+0.53%+1.96%+16.42%-30.22% 13.02B
Average +0.18%-0.57%+64.28%+98.48% 24.39B
Weighted average by Cap. -0.10%-0.64%+74.98%+119.58%

Financials

2018 2019
Net sales - -
Net income 25.3M 22.11M 20.4M 18.8M 35.44M 2.44B 36.23M 244M 95.91M 1.19B 95.01M 92.93M 4.11B 76.99M 67.28M 62.09M 57.23M 108M 7.41B 110M 742M 292M 3.63B 289M 283M 12.5B
Net Debt -253M -221M -204M -188M -354M -24.35B -362M -2.44B -959M -11.93B -950M -929M -41.05B -83.08M -72.6M -66.99M -61.75M -116M -8B -119M -801M -315M -3.92B -312M -305M -13.49B
Logo Mertiva AB
Mertiva AB, formerly Diamyd Medical AB, is a Sweden-based company active within the healthcare sector. As of August 31, 2013, the Company owned 8% shares of the United-States based Protein Sciences Corporation, as well as 19% shares of Mercodia AB. The Company changed its name in May 2013. Additionally, its subsidiary, Diamyd Therapeutics, was spun off and changed its name to Diamyd Medical.
Employees
-
  1. Stock Market
  2. Stocks
  3. MERT A Stock